The personalized mRNA cancer vaccine being co-developed by Moderna and U.S.-based Merck has met its primary endpoint in a Phase 3 melanoma trial, drawing renewed attention to a new combination strategy in cancer treatment. Because the cancer vaccine is being developed not to replace existing immuno-oncology drugs but to be used alongside them to enhance therapeutic efficacy, changes are expected in the future competitive landscape of the anticancer drug market.

■ Intismeran Autogene Combined with Keytruda Shows Improvement in Key Endpoints Over Monotherapy

The personalized mRNA cancer vaccine 'Intismeran Autogene,' developed by Moderna and Merck, underwent its Phase 3 trial in combination with the immuno-oncology drug Keytruda. According to the announced results, the combination therapy of Intismeran Autogene and Keytruda showed improvements in key treatment indicators compared to Keytruda monotherapy. It met both the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS), with no new safety concerns identified.

■ Personalized mRNA Vaccine Confirms Therapeutic Potential in Large-Scale Confirmatory Trial

A particularly notable aspect of these results is that the personalized mRNA cancer vaccine confirmed its therapeutic potential in a large-scale confirmatory clinical trial. Cancer vaccines are being developed to induce the immune system to recognize cancer cells more precisely based on the characteristics of each patient's tumor. Rather than replacing existing anticancer drugs, the central strategy is to use them together with immuno-oncology drugs to strengthen anticancer effects.

Moderna is also expanding its combination research with Keytruda beyond melanoma to other cancer types, including non-small cell lung cancer. This suggests that cancer vaccines are likely to establish themselves as a platform that enhances treatment outcomes in combination with existing anticancer drugs, rather than as an independent treatment modality.

■ Interpretation: 'Commercialization of Cancer Vaccines ≠ Shrinkage of Existing Anticancer Drug Market'

Accordingly, caution is needed regarding interpretations that the commercialization of cancer vaccines will directly lead to a shrinking market for existing anticancer drugs. In cancer treatment, multiple therapies are often used together depending on the patient's condition, cancer type, and stage of treatment. Even with the emergence of new treatment technologies, rather than the role of existing therapeutics disappearing, the market is more likely to expand through an increase in combinable treatment options.

In particular, for companies with their own novel anticancer drugs, combination with cancer vaccines presents a new development opportunity to enhance treatment efficacy or expand indications.

■ HLB Developing RNA Cancer Vaccine Through Immunomic... ITI-5000 in Phase 1 Trial

The HLB Group is also participating in cancer vaccine development. HLB's U.S. subsidiary, Immunomic Therapeutics, is developing an RNA cancer vaccine based on its own immunotherapy vaccine platform, 'UNITE.' UNITE is a platform designed to deliver specific antigens to immune cells and induce antigen-specific immune responses.

Immunomic is developing the cancer vaccine candidate 'ITI-5000,' which applies self-amplifying RNA technology to this platform. ITI-5000 is currently in a Phase 1 trial targeting triple-negative breast cancer, with the first patient enrolled and dosed in July. The trial is evaluating not only ITI-5000 monotherapy but also a treatment strategy combining it with pembrolizumab (the active ingredient in Keytruda).

Self-amplifying RNA is a technology designed to enable RNA to amplify itself within the body. It is being developed with the aim of inducing sufficient antigen expression even at relatively low doses and is being studied as one of the next-generation RNA therapeutic technologies.

■ HLB Still in Early Stages... Too Early to Interpret as Direct Success, Future Clinical Data Will Be Key

Moderna's Phase 3 results are significant in showing that the cancer vaccine field is advancing beyond early research into an actual treatment strategy. At the same time, the likelihood is growing that combination strategies pairing cancer vaccines with existing immuno-oncology drugs will become a major pillar of future anticancer drug development.

From HLB's perspective, since Immunomic's ITI-5000 trial is still in its early stages, it is too early to interpret Moderna's achievement as a direct development success for the company. However, the clinical progress in global cancer vaccine development is presenting new research directions for companies developing RNA-based cancer vaccines and combination therapies.

Going forward, the safety, immune response, and early clinical data of ITI-5000 in both monotherapy and combination with pembrolizumab are expected to be key variables in assessing the competitiveness of the HLB Group's cancer vaccine business.

[※ This article is based on information related to clinical trials and drug development by biotech and pharmaceutical companies and does not recommend the purchase or sale of specific stocks or guarantee investment returns. Clinical trial results may change through follow-up studies and regulatory review processes, and early clinical results do not imply final commercialization. Investment decisions and the responsibility for them rest with the investor. This article was written with AI assistance.]